The role of HLA-G molecule and HLA-G gene polymorphisms in tumors, viral hepatitis, and parasitic diseases

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

Peginterferon-alpha plus ribavirin is the most effective therapy for chronic hepatitis C. This study was designed to evaluate the effect of peginterferon alpha-2a (40 kDa) plus ribavirin on sustained virological response (SVR) when administered for 24 vs 48 weeks in genotype 1 naive patients. One hundred and seventeen patients were enrolled in this controlled trial. Genotype 1 patients were randomized to 24 weeks treatment vs 48 weeks treatment. Genotype non-1 patients received 24 weeks treatment as an observational group. Outcomes were SVR (defined by hepatitis C virus-RNA-negative at week 24 of follow-up) and tolerability across the study period. The end-of-treatment response was 59% for genotype 1 (24 weeks treatment), 80% for genotype 1 (48 weeks treatment) and 92% for genotype non-1 (24 weeks treatment). The end-of-follow-up response was 19% (95% confidence interval (CI): 7.2-36.4) (genotype 1, 24 weeks) and 48% (95% CI: 30.2-66.9; P = 0.0175) (genotype 1, 48 weeks). Among genotype non-1, SVR was 76% (95% CI: 62.3-86.5). There were no unexpected adverse events.Almost half of the genotype 1 patients achieved an SVR after 48 weeks treatment with peginterferon alpha-2a (40 kDa) and low-dose ribavirin and confirmed that they should be treated for 48 weeks. Safety profile was acceptable.

Serologic profile in hepatitis B virus and hepatitis C virus in a Brazilian liver transplant waiting list

Chronic viral hepatitis is currently the most common indication for liver transplantation (OLT). Knowing the serological profile of patients on the liver transplant waiting list (LTWL) is essential to manage prophylactic and therapeutic strategies pre- and post-OLT. The aim of this study was to determine the hepatitis B virus (HBV) and hepatitis C virus (HCV) serological profile on the LTWL.Methods. Serological data were collected from 44 candidates included on, the LTWL from May 2003 to November 2004. HBV and HCV serological profiles were performed by microenzyme immunoassay.Results. Twenty-eight patients (66.7%) lacked H13V serological markers. Anti-HBs was detected in 9.5% and was positive for HBsAg, anti-HBc, IgM anti-HBc, or HbeAg in 4.8% of patients, probably related to reactivation of chronic infection. In 7.1% of patients, the markers demonstrated serological cure of infection. In HCV patients, 41.5% were positive. There was H13V and HCV co-infection in 12.2% of patients.Conclusion. HBV infection in 21.4% of the patients corroborates the need to use more efficient protocols for prophylactic and therapeutic management pre- and post-OLT. The high prevalence of HCV infection reinforces the need to follow adequate protocols to avoid related complications and guarantee rational and universal use of more efficient drugs.

Liver HLA-G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Validação de recursos de cargas viral do HIV-1 obtidos para insumos/kids/equipamentos de diferentes procedênias

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Vírus da hepatite B: avaliação da resposta sorológica à vacina em funcionários de limpeza de hospital-escola

A hepatite viral B constitui um dos mais importantes problemas de saúde pública em todos os continentes. O vírus da hepatite B se transmite por via parenteral e, sobretudo, por via sexual. O objetivo foi avaliar a população ativa dos funcionários de limpeza do hospital da Faculdade de Medicina de Botucatu-UNESP, que receberam esquema completo de vacinação contra a hepatite B, medir os níveis de anticorpo contra o AgHBs (anti-HBs) e avaliar a sua relação com as condições epidemiológicas gerais, de vida pessoal e profissional e de risco de infecção pelo vírus da hepatite B.

Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Detecção in vitro da hepatite C (VHC) em plaquetas provenientes de indivíduoas não infectados expostas ao vírus

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Estudo de correlação entre as provas bioquímicas de função hepática, no diagnóstico de hepatite aguda pelo vírus da hepatite A em crianças

Pós-graduação em Pediatria - FMB

Qualidade de vida e morbidade psicológica de pacientes portadores de hepatite C em tratamento com interferon peguilado e ribavirina

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeito do uso do cogumelo Agaricus brasiliensis no estado nutricional, na frequência e intensidade dos efeitos adversos da terapia medicamentosa e na resposta bioquímica hepática em indivíduos com hepatite crônica pelo vírus C: estudo prospectivo, randomizado, duplo cego, placebo controlado

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Desenvolvimento de sistema de educação continuada a distância e interconsulta em hepatites virais

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Análise da prevalência e de fatores de risco para as hepatites virais crônicas B e C em idosos residentes no município de Botucatu-SP

Pós-graduação em Fisiopatologia em Clínica Médica - FMB

Um Modelo Espacial para a Resposta Imunológica Adaptativa da Hepatite B

This paper proposed a two-dimensional spatial model to describe the adaptive immune response for viral hepatitis B. This model considered six populations: healthy hepatocytes T, infected hepatocytes Y , hepatitis B virus V , innate immune system I, active immune system X and memory cells, X. First, a compartmental model was constructed and its equilibrium solutions and also the threshold values related to the stability of each solution were obtained. Using this model, we was able to reproduce the different trends observed for the disease, which are: individuals that eliminate the infection without forming immune response, patients with acute and chronic carriers. By including dispersion of defense cells of the immune system and virus (spatial model), we analyze two situations: homogeneous model, in which the model parameters are the same at all points of the network, and heterogeneous model, which characterizes cells more permeable and less permeable to virus invasion. For the two spatial models (homogeneous and heterogeneous) the times relatead to the viral erradication and/or virus invasion and persistence becoming smaller in relation to the compartmental model. The results also showed that for the set of values used in the simulations and if the two diffusion rates are different from zero, the model is sensitive to variations in the rate of viral spread and not dependent on the dispersion of memory cells. Finally, the heterogeneous model when compared to the homogeneous model shows that the infection can be spatially limited depending on the type of the cell involved in the infection process

Consultas de enfermagem com pacientes em tratamento para hepatite C

Infection with hepatitis C virus (HCV) is a worldwide problem of public health and who estimates 2.5% to 4.9% of infection by this virus among the population. This means that there are 3.9 to 7.6 million people at risk of developing cirrhosis or liver cancer. In Brazil, 20% to 58% of patients with chronic liver disease have antibodies to HCV (anti-HCV). To characterize the profile of patients undergoing treatment for hepatitis C in the Ambulatory General HC-FMB/UNESP, identify aspects of the disease and the phases of nursing process addressed during consultation. Transverse and descriptive study involving 38 patients undergoing treatment for Hepatitis C in Ambulatory General Area (Viral Hepatitis) in the period from July to September 2010. The population consisted of 38 patients, most of the males with completed higher education level, Catholic, married and aged predominantly between 41 and 60 years. Among the drugs used, we find the use of antihypertensive, antidepressant / anxiolytic and antidiabetic / hypoglycemic. With respect to specific medications used to treat hepatitis C, we found the use mainly of alfapeguinterferona 2b + ribavirin. The drugs used were complementary erythropoietin and filgastrim. There was a predominance of fibrosis 2 (F2) and genotype 1 (G1). Regarding the means of contamination, it was stressed blood transfusion and injection drug use. The most frequent drug reactions were decreased appetite, weight loss and discouragement. : The Nursing Process is considered a valuable tool in caring for patients with hepatitis C, because it works as identifying aspects of lifestyle, needs and potential of these patients and allows the deployment of humanized care strategies aimed at reduction of health hazards and improving the quality of life of these patients